Recco Bio-B (02179) obtains new adjuvant recombinant shingles vaccine REC610 phase III clinical trial summary report

Zhitong Finance App News, Recco Bio-B (02179) announced that the phase III clinical trial of REC610, a new adjuvant recombinant herpes zoster vaccine independently developed by the group, has been completed. Registration number: CTR20243742. The company has recently obtained the clinical trial summary report of this study.

According to reports, REC610 is a new adjuvant recombinant herpes zoster vaccine independently developed by the company. It uses varicella-zoster virus (VZV) glycoprotein E (gE) protein as an antigen, and is equipped with a novel adjuvant BFA01 independently developed by the company. BfA01 can promote the production of high levels of Ge-specific CD4+ T cells and antibodies. REC610 is suitable for shingles prevention in adults aged 40 and above. If REC610 is finally approved for marketing, it will provide more options for domestic vaccinators and help meet clinical needs in the field of shingles prevention in China.

According to the summary report and the information available as of the date of this announcement, the study was successfully implemented and completed according to the research plan. REC610 showed good overall safety and immunogenicity in this study.

Following the completion of the summary report, the company will actively communicate with the National Drug Administration (NMPA) and the Drug Evaluation Center (CDE) of the People's Republic of China to fully advance the product declaration and review process.